Klonopin (clonazepam) 2mg cannot be bought online through home-first digital care routes as a Schedule IV controlled substance requiring a valid EPCS prescription from a DEA-registered US healthcare provider for panic disorder or seizures; prescription-free digital services violate 21 U.S.C. § 841 federal felony distribution laws with up to 20-year imprisonment penalties.
Dosing starts at 0.25mg BID titrating to 2mg BID maximum 4mg/day divided under 2025 guidelines, with DEA telemedicine flexibilities expiring December 31, 2025 mandating synchronous HIPAA video PDSS ≥15 confirmation and multi-state PDMP clearance—no home-first route bypasses EPCS or post-flex in-person exams across 50 states.
Clonazepam 2mg (GABA-A α2/α3 agonist Ki 0.5nM), Tmax 1-4h, t½ 30-40h active 7-aminoclonazepam; black box dependence 40% week 4, opioid respiratory OR10, withdrawal seizures 20-30%—taper 0.25mg weekly 8-12 weeks CIWA-B; contraindications glaucoma, COPD AHI>30, CYP3A4i x3 exposure.
Diagnostic: PDSS ≥15 + 6-month collateral or EEG seizure exclusion.
Screening: PDMP clean, C-SSRS negative, QTc <450ms.
EPCS: #90 tabs 2mg ≤5 refills/6mo signature delivery.
Monitoring: ≥30% PDSS q30d + UDS/pill counts.
| Incidence | Effect | Risk Factors | Management |
|---|---|---|---|
| 25-45% | Sedation/ataxia | >2mg elderly | BID lowest dose falls |
| 15-30% | Amnesia/depression | >8 weeks | MoCA q4w taper |
| 10-20% | Respiratory OR10 | Opioids | Naloxone standby |
| 5-15% | Agitation | SUD history | SSRI switch |
| 1-5% | Seizures | Abrupt stop | Lorazepam bridge |
Home-first digital care route violates CSA Schedule IV (21 CFR 1306.04), Ryan Haight mandates (21 USC 802(54))—federal felony per transaction.
| Supporters | |||
| Name | Date | Amount | Comments |
| Total | $0.00 | ||